The research progress of SARS-CoV-2 main protease inhibitors from 2020 to 2022

被引：66

作者：

Pang, Xiaojing ^{[1
]}

Liu, Yang ^{[1
]}

Li, Hua ^{[1
,2
]}

Chen, Lixia ^{[1
]}

机构：

[1] Shenyang Pharmaceut Univ, Wuya Coll Innovat, Key Lab Struct Based Drug Design & Discovery, Minist Educ, Shenyang 110016, Peoples R China

[2] Fujian Univ Tradit Chinese Med, Inst Struct Pharmacol & TCM Chem Biol, Coll Pharm, Fuzhou 350122, Peoples R China

来源：

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY | 2023年 / 257卷

基金：

中国国家自然科学基金;

关键词：

COVID-19; SARS-CoV-2; M pro inhibitors; Drug repurposing; Drug design; COVALENT INHIBITORS; GENOME SEQUENCE; ACHILLES-HEEL; CORONAVIRUS; DISCOVERY; EBSELEN; IDENTIFICATION; REPLICATION; DESIGN; 3C;

D O I：

10.1016/j.ejmech.2023.115491

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide. The main protease (Mpro) of SARS-CoV-2 plays a central role in viral replication and transcription and represents an attractive drug target for fighting COVID-19. Many SARS-CoV-2 Mpro inhibitors have been reported, including covalent and noncovalent inhibitors. The SARS-CoV-2 Mpro inhibitor PF-07321332 (Nirmatrelvir) designed by Pfizer has been put on the market. This paper briefly introduces the structural characteristics of SARS-CoV-2 Mpro and summarizes the research progress of SARS-CoV-2 Mpro inhibitors from the aspects of drug repurposing and drug design. These information will provide a basis for the drug development of treating the infection of SARS-CoV-2 and even other coronaviruses in the future.

引用

页数：20

共 107 条

[1]

Afshar S., 2020, AVICENNA J MED BIOCH, V8, P83

[2] Fight against novel coronavirus: A perspective of medicinal chemists [J].

Amin, Sk Abdul ;

Jha, Tarun .

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2020, 201

[3] Coronavirus main proteinase (3CLpro) structure:: Basis for design of anti-SARS drugs [J].

Anand, K ;

Ziebuhr, J ;

Wadhwani, P ;

Mesters, JR ;

Hilgenfeld, R .

SCIENCE, 2003, 300 (5626) :1763-1767

[4] Identification of novel inhibitors of the SARS coronavirus main protease 3CLpro [J].

Bacha, U ;

Barrila, J ;

Velazquez-Campoy, A ;

Leavitt, SA ;

Freire, E .

BIOCHEMISTRY, 2004, 43 (17) :4906-4912

[5] Teicoplanin: an alternative drug for the treatment of COVID-19? [J].

Baron, Sophie Alexandra ;

Devaux, Christian ;

Colson, Philippe ;

Raoult, Didier ;

Rolain, Jean-Marc .

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2020, 55 (04)

[6] The global distribution and burden of dengue [J].

Bhatt, Samir ;

Gething, Peter W. ;

Brady, Oliver J. ;

Messina, Jane P. ;

Farlow, Andrew W. ;

Moyes, Catherine L. ;

Drake, John M. ;

Brownstein, John S. ;

Hoen, Anne G. ;

Sankoh, Osman ;

Myers, Monica F. ;

George, Dylan B. ;

Jaenisch, Thomas ;

Wint, G. R. William ;

Simmons, Cameron P. ;

Scott, Thomas W. ;

Farrar, Jeremy J. ;

Hay, Simon I. .

NATURE, 2013, 496 (7446) :504-507

[7]

Bondeson DP, 2015, NAT CHEM BIOL, V11, P611, DOI [10.1038/NCHEMBIO.1858, 10.1038/nchembio.1858]

[8]

Boras Britton, 2021, bioRxiv, DOI 10.1101/2020.09.12.293498

[9] A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster [J].

Chan, Jasper Fuk-Woo ;

Yuan, Shuofeng ;

Kok, Kin-Hang ;

To, Kelvin Kai-Wang ;

Chu, Hin ;

Yang, Jin ;

Xing, Fanfan ;

Liu, Jieling ;

Yip, Cyril Chik-Yan ;

Poon, Rosana Wing-Shan ;

Tsoi, Hoi-Wah ;

Lo, Simon Kam-Fai ;

Chan, Kwok-Hung ;

Poon, Vincent Kwok-Man ;

Chan, Wan-Mui ;

Ip, Jonathan Daniel ;

Cai, Jian-Piao ;

Cheng, Vincent Chi-Chung ;

Chen, Honglin ;

Hui, Christopher Kim-Ming ;

Yuen, Kwok-Yung .

LANCET, 2020, 395 (10223) :514-523

[10] Liberation of SARS-CoV main protease from the viral polyprotein: N-terminal autocleavage does not depend on the mature dimerization mode [J].

Chen, Shuai ;

Jonas, Felix ;

Shen, Can ;

Higenfeld, Rolf .

PROTEIN & CELL, 2010, 1 (01) :59-74

← 1 2 3 4 5 6 7 8 9 10 →